Who are BG00012 (DMF)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Drug: Carfilzomib + Lenalidomide + Dexamethasone, Glatiramer acetate (GA), FTY720, PF-06863135 + lenalidomide, Ixazomib plus low-dose lenalidomide, Interferon-Alpha.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bg00012-dmf.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

BG00012 (DMF) — Competitive Intelligence Brief

BG00012 (DMF) (BG00012 (DMF)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fumaric acid ester; immunomodulator. Area: Neurology / Immunology.

marketed Fumaric acid ester; immunomodulator Nrf2 (nuclear factor erythroid 2-related factor 2) Neurology / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

BG00012 (DMF) (BG00012 (DMF)) — Biogen. BG00012 (dimethyl fumarate) activates the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway to reduce oxidative stress and neuroinflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BG00012 (DMF) TARGET	BG00012 (DMF)	Biogen	marketed	Fumaric acid ester; immunomodulator	Nrf2 (nuclear factor erythroid 2-related factor 2)
Drug: Carfilzomib + Lenalidomide + Dexamethasone	Drug: Carfilzomib + Lenalidomide + Dexamethasone	Amgen	marketed	Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination	20S proteasome (carfilzomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
Glatiramer acetate (GA)	Glatiramer acetate (GA)	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Immunomodulator; disease-modifying therapy (DMT)
FTY720	FTY720	Novartis Pharmaceuticals	marketed	Sphingosine-1-phosphate receptor modulator; Immunomodulator	Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)
PF-06863135 + lenalidomide	pf-06863135-lenalidomide	Pfizer	marketed	small molecule + immunomodulatory drug	unknown
Ixazomib plus low-dose lenalidomide	Ixazomib plus low-dose lenalidomide	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Proteasome inhibitor and immunomodulatory agent	Proteasome and cereblon
Interferon-Alpha	Interferon-Alpha	University of Birmingham	marketed	Cytokine; Immunomodulator	Interferon-alpha receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fumaric acid ester; immunomodulator class)

Biogen · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BG00012 (DMF) — Competitive Intelligence Brief. https://druglandscape.com/ci/bg00012-dmf. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab